We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

107 hedge funds and large institutions have $627M invested in Cymabay Therapeutics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 8

236% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $447K

100% more capital invested

Capital invested by funds: $314M → $627M (+$313M)

42% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 26

34% more funds holding

Funds holding: 80 → 107 (+27)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

Holders
107
Holders Change
+27
Holders Change %
+33.75%
% of All Funds
2.45%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
36
Increased
37
Reduced
26
Closed
8
Calls
$1.5M
Puts
$447K
Net Calls
+$1.05M
Net Calls Change
+$810K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$40.5M
2
BC
Boxer Capital
California
+$21.1M
3
DM
Deerfield Management
New York
+$15.1M
4
Millennium Management
Millennium Management
New York
+$13.6M
5
FCMI
Foresite Capital Management III
California
+$12M

Top Sellers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
-$10.9M
2
FCM
Farallon Capital Management
California
-$6.83M
3
AAP
Ardsley Advisory Partners
Connecticut
-$5.28M
4
SFM
Sphera Funds Management
Israel
-$2.21M
5
PC
Polar Capital
United Kingdom
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
101
Prelude Capital Management
New York
$12K +$5.17K +416 +85%
Citigroup
102
Citigroup
New York
$12K +$11.4K +918 New
CG
103
Cutler Group
California
$10K +$4.97K +400 +100%
SFM
104
Signet Financial Management
New Jersey
$9K +$8.39K +675 New
LTFS
105
Ladenburg Thalmann Financial Services
Florida
$4K -$17.8K -1,435 -83%
AIS
106
Accurate Investment Solutions
Pennsylvania
$4K – – –
Federated Hermes
107
Federated Hermes
Pennsylvania
$2K +$2.14K +172 New
SFM
108
Sphera Funds Management
Israel
– -$2.21M -240,000 Closed
GCP
109
GSA Capital Partners
United Kingdom
– -$609K -66,200 Closed
VF
110
Virtu Financial
New York
– -$228K -24,735 Closed
TI
111
Trexquant Investment
Connecticut
– -$207K -22,511 Closed
EMG
112
Ellington Management Group
Connecticut
– -$190K -20,600 Closed
DCM
113
Delpha Capital Management
New York
– -$22K -2,350 Closed
PSC
114
Piper Sandler & Co
Minnesota
– -$7K -800 Closed
CHP
115
Cable Hill Partners
Oregon
– -$5K -500 Closed
1 2 3 4
5

CBAY Hedge Fund Activity: Q1 2018 in Review

107 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2018, worth a combined $627M — up 100% from $314M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new CBAY positions and 8 closed out — a net gain of 28 holders — while 37 added to existing stakes and 26 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $40.5M. The largest seller was Abingworth, cutting an estimated $10.9M.

  • 107 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2018, up from 80 in Q4 2017.
  • Funds reported $627M of Cymabay Therapeutics stock for Q1 2018, up 100% quarter-over-quarter.
  • 36 funds opened new Cymabay Therapeutics positions in Q1 2018 and 8 closed out, a net change of +28 holders.
  • The largest Cymabay Therapeutics buyer in Q1 2018 was Fidelity Investments, an estimated $40.5M added.
  • The largest Cymabay Therapeutics seller in Q1 2018 was Abingworth, an estimated $10.9M sold.

Based on aggregated 13F filings for Q1 2018.